

Kevin J Barnham

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7738573/publications.pdf>

Version: 2024-02-01

23
papers

1,481
citations

567281

15
h-index

580821

25
g-index

27
all docs

27
docs citations

27
times ranked

2912
citing authors

#	ARTICLE	IF	CITATIONS
1	Loss-of-function and gain-of-function studies refute the hypothesis that tau protein is causally involved in the pathogenesis of Huntington's disease. <i>Human Molecular Genetics</i> , 2022, 31, 1997-2009.	2.9	2
2	Quantification of N-terminal amyloid- β^2 isoforms reveals isomers are the most abundant form of the amyloid- β^2 peptide in sporadic Alzheimer's disease. <i>Brain Communications</i> , 2021, 3, fcab028.	3.3	25
3	ATH434 Reverses Colorectal Dysfunction in the A53T Mouse Model of Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1821-1832.	2.8	5
4	Cu ^{II} (at5m) inhibits ferroptosis: Implications for treatment of neurodegenerative disease. <i>British Journal of Pharmacology</i> , 2020, 177, 656-667.	5.4	92
5	Reduced striatal vesicular monoamine transporter 2 in REM sleep behavior disorder: imaging prodromal parkinsonism. <i>Scientific Reports</i> , 2020, 10, 17631.	3.3	10
6	Parkinsonism as a Third Wave of the COVID-19 Pandemic?. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1343-1353.	2.8	50
7	S-Adenosylmethionine Rescues Cognitive Deficits in the rTg4510 Animal Model by Stabilizing Protein Phosphatase 2A and Reducing Phosphorylated Tau. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1705-1715.	2.6	11
8	Small RNA fingerprinting of Alzheimer's disease frontal cortex extracellular vesicles and their comparison with peripheral extracellular vesicles. <i>Journal of Extracellular Vesicles</i> , 2020, 9, 1766822.	12.2	59
9	Ablation of tau causes an olfactory deficit in a murine model of Parkinson's disease. <i>Acta Neuropathologica Communications</i> , 2018, 6, 57.	5.2	11
10	Modulating Protein Phosphatase 2A Rescues Disease Phenotype in Neurodegenerative Tauopathies. <i>ACS Chemical Neuroscience</i> , 2018, 9, 2731-2740.	3.5	16
11	Characterization and Identification of Dityrosine Cross-Linked Peptides Using Tandem Mass Spectrometry. <i>Analytical Chemistry</i> , 2017, 89, 6136-6145.	6.5	70
12	A rigorous method to enrich for exosomes from brain tissue. <i>Journal of Extracellular Vesicles</i> , 2017, 6, 1348885.	12.2	218
13	The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease. <i>Acta Neuropathologica Communications</i> , 2017, 5, 53.	5.2	77
14	Neurological Dysfunction in Early Maturity of a Model for Niemann-Pick C1 Carrier Status. <i>Neurotherapeutics</i> , 2016, 13, 614-622.	4.4	17
15	Peripheral β -Defensins 1 and 2 are Elevated in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 1131-1143.	2.6	15
16	A Functional Role for β in Metal Homeostasis? N-Termination and High-Affinity Copper Binding. <i>Angewandte Chemie - International Edition</i> , 2015, 54, 10460-10464.	13.8	102
17	The N-Terminal Residues 43 to 60 Form the Interface for Dopamine Mediated β -Synuclein Dimerisation. <i>PLoS ONE</i> , 2015, 10, e0116497.	2.5	10
18	High Order W ² -Reactive Stable Oligomers of Amyloid- β^2 are Produced in vivo and in vitro via Dialysis and Filtration of Synthetic Amyloid- β^2 Monomer. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 69-78.	2.6	2

#	ARTICLE	IF	CITATIONS
19	Stabilization of Nontoxic A β -Oligomers: Insights into the Mechanism of Action of Hydroxyquinolines in Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2015, 35, 2871-2884.	3.6	67
20	PBT2 inhibits glutamate-induced excitotoxicity in neurons through metal-mediated preconditioning. <i>Neurobiology of Disease</i> , 2015, 81, 176-185.	4.4	17
21	A β ² -amyloid in biological samples: not all A β ² detection methods are created equal. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 203.	3.4	3
22	Biological metals and metal-targeting compounds in major neurodegenerative diseases. <i>Chemical Society Reviews</i> , 2014, 43, 6727-6749.	38.1	417
23	Oral Treatment with Cull(atm) Increases Mutant SOD1 In Vivo but Protects Motor Neurons and Improves the Phenotype of a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis. <i>Journal of Neuroscience</i> , 2014, 34, 8021-8031.	3.6	161